Funding for this research was provided by:
the Ministry of Health, Labour and Welfare, Japan (the Respiratory Failure Research Group (H26-Intractable diseases-General-076))
the Japan Agency for Medical Research and Development (a grant to the Pulmonary Hypertension Research Group (15ek0109127h0001))
the Japanese Ministry of Education and Science. (a Grant-in-Aid for Scientific Research (JSPS KAKENHI Grant Number 15K09210))
Text and Data Mining valid from 2018-12-01
Received: 12 February 2018
Accepted: 18 December 2018
First Online: 29 December 2018
Ethics approval and consent to participate
: The study protocol was approved by the institutional review board of Chiba University (approval number 353 and 1248), and written informed consent was obtained from all of the participating patients.
: Not applicable.
: Dr.Naito is a member of endowed department from Teijin Pharma ltd. and Ono Pharmaceutical Co. ltd. outside the submitted work. Dr. Sakao received honoraria for lectures from Nippon Shinyaku Co., Ltd., GlaxoSmithKline, Actelion Pharmaceuticals, and Pfizer. Dr. Tanabe is a member of endowed department from Actelion Pharmaceuticals Japan, has received grants from Nipponshinyaku, personal fees from Bayer, personal fees from Niiponshinyaku, personal fees from Pfizer, personal fees from GSK, personal fees from Actelion Pharmaceuticals Japan, outside the submitted work. Dr. Jujo is a member of endowed department from Actelion Pharmaceuticals Japan.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.